A scoping systematic assessment for post-marketing abuse drug withdrawal

Basit Öğe Kaydı
dc.authoridAnmar Al-Taie / 0000-0002-2183-6830en_US
dc.authoridAyşe Şeyma Büyük / 0000-0001-8934-0359en_US
dc.authoridSemra Şardaş / 0000-0001-5456-8636en_US
dc.authorscopusidSemra Şardaş / 7003286974
dc.authorscopusidAnmar Al-Taie / 57221579036
dc.authorscopusidAyşe Şeyma Büyük / 57215857903
dc.authorwosidAnmar Al-Taie / I-8549-2019en_US
dc.authorwosidAyşe Şeyma Büyük / AAM-1484-2020en_US
dc.authorwosidSemra Şardaş / J-2175-2018en_US
dc.contributor.authorAl-Taie, Anmar
dc.contributor.authorBüyük, Ayşe Şeyma
dc.contributor.authorŞardaş, Semra
dc.date.accessioned2022-06-17T13:59:10Z
dc.date.available2022-06-17T13:59:10Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümüen_US
dc.description.abstractObjectives The aim of this study was to identify the post-marketing withdrawal of medicines due to their adverse drug reactions (ADRs)-related abuse effects and to examine the types of evidence, mechanisms and patterns for the withdrawal decisions after their approval across different geographical regions. Methods By searching through different databases that focused on withdrawn drugs due to their ADRs-related abuse effects between 1930 and 2021 that could provide findings of evidence used in making withdrawal decisions based on the tools of the Oxford Centre for Evidence-Based Medicine (OCEBM) criteria alongside sources derived from authorities based on their withdrawal. The outcomes were categorized, and the average time between the launch date of exposure and withdrawal was calculated and stratified. Key findings A total of 33 abused withdrawn drugs. The withdrawals occurred between 1961 and 2007. Psychostimulant drugs accounted for most of the abuse withdrawals (42.4%). Most of the withdrawals occurred between 1981 and 1990 (n = 18, 54.5%). Most withdrawn drugs were in Europe (41, 46.6%) with a minimum withdrawal period of 5 years and an average time of withdrawal of 28.8 years. Conclusions Psychostimulant drugs presented the most abuse withdrawals based on the evidence of case-control studies, and the most withdrawals were in Europe. The duration of withdrawn drugs was different from region to region in different continents. More intensive research is required to further reduce the time duration between drug marketing and withdrawal, which will help improve decision-making processes with favourable benefit-risk ratio outcomes.en_US
dc.identifier.citationAl-Taie, A., Buyuk, A. S., Sardas, S. (2022). A scoping systematic assessment for post-marketing abuse drug withdrawal. Journal of Pharmaceutical Health Services Research.en_US
dc.identifier.doi10.1093/jphsr/rmac010en_US
dc.identifier.issn1759-8885en_US
dc.identifier.uridoi.org/10.1093/jphsr/rmac010
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2924
dc.identifier.wosWOS:000805234200001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.institutionauthorAl-Taie, Anmar
dc.institutionauthorBüyük, Ayşe Şeyma
dc.institutionauthorŞardaş, Semra
dc.language.isoenen_US
dc.publisherOXFORD UNIV PRESSen_US
dc.relation.ispartofJOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCHen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdverse Drug Reactionsen_US
dc.subjectDrug Withdrawalen_US
dc.subjectAbuseen_US
dc.subjectEuropeen_US
dc.subjectCNS Stimulationen_US
dc.subjectPsychostimulant Drugsen_US
dc.titleA scoping systematic assessment for post-marketing abuse drug withdrawalen_US
dc.typeArticleen_US

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Eczacılık Meslek Bilimleri Bölümü Makale Koleksiyonu